IDEAYA Biosciences, Inc.
IDYA
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methyltā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$37.59
Price+0.37%
$0.14
1Y
Price
Market Cap
$3.574b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-1368.1%
EBITDA Margin-1269.6%
Net Profit Margin-1865.3%
Free Cash Flow Margin-1368.1%
EBITDA Margin-1269.6%
Net Profit Margin-1865.3%
Free Cash Flow MarginRevenue
$234.127m
+7.0%
1y CAGR+987.1%
3y CAGR+726.8%
5y CAGREarnings
-$175.020m
-53.9%
1y CAGR-46.1%
3y CAGR-57.7%
5y CAGREPS
-$1.94
-51.6%
1y CAGR-20.4%
3y CAGR-24.8%
5y CAGRBook Value
$1.199b
$1.310b
Assets$110.794m
Liabilities$29.307m
DebtDebt to Assets
2.2%
-0.1x
Debt to EBITDAFree Cash Flow
-$190.008m
-158.6%
1y CAGR-67.2%
3y CAGR-57.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company